Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.
about
Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trialsUnraveling the pathogenesis of HIV peripheral neuropathy: insights from a simian immunodeficiency virus macaque modelInhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient DataThe NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytesRandomized, Double-Blind, Crossover Trial of Amitriptyline for Analgesia in Painful HIV-Associated Sensory NeuropathyOver-reported peripheral neuropathy symptoms in a cohort of HIV infected and uninfected Rwandan women: the need for validated locally appropriate questionnaires.Pain in amaXhosa women living with HIV/AIDS: a cross-sectional study of ambulant outpatientsScreening for HIV-associated peripheral neuropathy in resource-limited settingsHIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter.Loss of corneal sensory nerve fibers in SIV-infected macaques: an alternate approach to investigate HIV-induced PNS damage.Utility of quantitative sensory testing and screening tools in identifying HIV-associated peripheral neuropathy in Western Kenya: pilot testing.Practicalities and challenges in re-orienting the health system in Zambia for treating chronic conditions.Role of metabolic syndrome components in HIV-associated sensory neuropathy.Genetic variation in iron metabolism is associated with neuropathic pain and pain severity in HIV-infected patients on antiretroviral therapy.Sensory, psychological, and metabolic dysfunction in HIV-associated peripheral neuropathy: A cross-sectional deep profiling study.Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathiesSterile alpha motif and histidine/aspartic acid domain-containing protein 1 (SAMHD1)-facilitated HIV restriction in astrocytes is regulated by miRNA-181a.Optimizing measures of HIV-associated neuropathyCaffeine Blocks HIV-1 Tat-Induced Amyloid Beta Production and Tau Phosphorylation.Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapyNeuroinflammation and virus replication in the spinal cord of simian immunodeficiency virus-infected macaques.Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study.Prevalence of peripheral neuropathy and its associated demographic and health status characteristics, among people on antiretroviral therapy in Rwanda.Microglial content-dependent inhibitory effects of calcitonin gene-related peptide (CGRP) on murine retroviral infection of glial cells.Role of TNF block genetic variants in HIV-associated sensory neuropathy in black Southern Africans.Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study.Pharmacological induction of CCL5 in vivo prevents gp120-mediated neuronal injury.Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapyPredictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy.Peripheral neuropathy in HIV: prevalence and risk factorsThe impact of HIV/AIDS on compliance with antidepressant treatment in major depressive disorder: A prospective study in a South African private healthcare cohortMacrophage-mediated dorsal root ganglion damage precedes altered nerve conduction in SIV-infected macaques.Neuropsychiatric complications of aging with HIV.Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa.Monocyte Traffic, Dorsal Root Ganglion Histopathology, and Loss of Intraepidermal Nerve Fiber Density in SIV Peripheral Neuropathy.Self-Injurious Behavior Secondary to Cytomegalovirus-Induced Neuropathy in an SIV-Infected Rhesus Macaque (Macaca mulatta)The relationship between race and HIV-distal sensory polyneuropathy in a large cohort of US womenQuantifying cognition at the bedside: a novel approach combining cognitive symptoms and signs in HIV.Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV.
P2860
Q21562140-22987839-9B9E-4C51-ABB4-787FDC13486EQ26825231-3FC40D5D-B2EF-4BB9-96DB-5EB00C4D5931Q28084769-95D8447F-D2B7-455D-80C1-6D9A79F1FE92Q28486204-1CD1E061-679A-427D-83D5-CEA751C225E6Q28547239-EA666197-FDFE-48CD-BD8B-1A9B8E72F197Q30390516-946B51DF-CC19-4634-839E-FD0BC4968F77Q33560824-DF0BF24B-4F42-490D-BFFF-B29A8F4DB6F4Q33603950-F9A4DEF7-E190-4AEB-A05C-5A607D276182Q33692525-6EAE115E-0BA0-4228-BA1C-2004F6994EF6Q33708704-7C0C3D7B-5199-43D7-AE0E-29A1E8DA6AD0Q33775705-5ED87370-A4D1-4BCE-AB2D-CE8CA62A0BF7Q33891075-F4C282C4-FE9F-44EE-8846-34DB10D5A177Q33960704-746675F9-9104-4AAD-8EB0-5AF08348AB73Q34075188-32FE22F8-1C07-48C8-88DD-616F3600288AQ34194723-B3F522EF-4E4C-43CA-A9D2-DD38F42AC46CQ34392451-7F36499F-66FE-4600-82FF-30A04FFD5278Q34472532-06BC2C5D-E984-47EE-A2C9-32CC38094544Q34476396-70B381E6-CC03-4C31-997A-722E171DD2A7Q34540333-2A1BF226-3F73-4DCD-8995-65CD778F903FQ34612023-40144E84-3E22-482E-8D5D-C4FF802F5947Q34734802-99D9A90B-0D1A-4942-89F2-56F3AC8EB593Q35057326-914D2151-A386-4063-84DF-3416FA8DD088Q35060210-B0838BFA-A984-43B9-8D8D-406A0D084286Q35075468-E0D2F912-214D-440F-9B91-A7634AF6711EQ35079928-FD7BB4CC-5747-4CA8-BD23-7519558D51FFQ35089902-E42C51DF-3623-470D-AC1C-FBBBFAC56F81Q35137844-918E3117-17A3-4D87-BB6E-E6F10F8D1643Q35164547-D31A9E92-7271-4362-AD6F-DEBDEE9C43D8Q35217892-26E0E786-1E1A-4701-8CDA-855BA2F58C31Q35384460-0A833022-9AA5-46B1-9F4D-1C6EA4910111Q35424733-9E779B35-07DF-4C4C-9AD8-FBF6A89047EFQ35474314-7CD825F7-EA31-4C99-BA99-3F5106CAB3CEQ35568407-4F45A7FA-BDD8-4BC4-B7B7-D31A72162F0AQ35689152-45A5A504-F659-43B6-8627-F62DA22692A4Q35751491-E7C70B8F-387E-4DBF-B9DF-7B4321DF6312Q35792802-F3593D20-1F26-4158-BF9D-84C14C3234C0Q35798495-D6CF5130-4346-4809-B5C4-2AE2B6817E87Q35823133-95B6760A-A48F-4B65-A9BE-2F8F42D6F752Q35840202-FE4B246A-9FDD-41E2-A917-186CA8FB1CBEQ35846104-64F4FB65-7778-41A8-8935-78E1799EE9B4
P2860
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Continued high prevalence and ...... al therapy: the CHARTER Study.
@en
Continued high prevalence and ...... al therapy: the CHARTER Study.
@nl
type
label
Continued high prevalence and ...... al therapy: the CHARTER Study.
@en
Continued high prevalence and ...... al therapy: the CHARTER Study.
@nl
prefLabel
Continued high prevalence and ...... al therapy: the CHARTER Study.
@en
Continued high prevalence and ...... al therapy: the CHARTER Study.
@nl
P2093
P2860
P50
P1433
P1476
Continued high prevalence and ...... al therapy: the CHARTER Study.
@en
P2093
Ann Collier
Benjamin B Gelman
CHARTER Study Group
Christina M Marra
David B Clifford
David Simpson
Debralee Rosario
Florin Vaida
J Hampton Atkinson
Justin C McArthur
P2860
P304
P356
10.1001/ARCHNEUROL.2010.76
P577
2010-05-01T00:00:00Z